solid cancer(s)
Conditions
Interventions
Study treatment is defined as spartalizumab as monotherapy or in combination
with other treatments intended to treat cancer, as defined in the parent
protocol.
Sponsors
Novartis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Subject is currently enrolled in a pre-defined Novartis-sponsored study and is receiving spartalizumab as single agent or in combination with other study treatment. 3. Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator. 4. Subject has demonstrated compliance, as assessed by the investigator, with the parent protocol requirements. 5. Subject is willing and able to comply with the scheduled visits and treatment plans.
Exclusion criteria
Exclusion criteria: Subject has been permanently discontinued from spartalizumab in the parent protocol for any reason other than enrollment in the CPDR001X2X01B study. Subject does not meet the criteria specified in the parent protocol criteria for continued study treatment. Subject not willing to comply with the contraception requirements outlined in the exclusion criteria of the parent protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To collect safety and tolerability data for spartalizumab as single agent or in combination with other study treatments | — |
Secondary
| Measure | Time frame |
|---|---|
| To allow subjects enrolled in a spartalizumab Novartis-sponsored study continued access to study treatment | — |
Countries
Netherlands
Outcome results
None listed